CMS is so Rare That it Took Four Years to Enroll Twenty People for a Trial

  According to a recent article in Biospace, Catalyst Pharmaceutical’s CMS-001 Phase 3 study ended with mixed results. The trial was billed as the first placebo-controlled double-blind study testing amifampridine phosphate (brand…

Continue Reading CMS is so Rare That it Took Four Years to Enroll Twenty People for a Trial